NovoCare vs. LillyDirect: Brand-Name Savings Programs Head-to-Head
Price verification — October 26, 2026
This article includes an older pricing snapshot. Older amounts, coupons and annual totals below are historical illustrations, not current checkout quotes.
- Wegovy (semaglutide): Wegovy tablet: $149/30 tablets at 1.5 mg, $199 at 4 mg (a temporary $149 4 mg offer may apply), and $299 at 9 mg or 25 mg. Wegovy injection: eligible new patients may pay $199 per 28-day fill for the first two fills at 0.25 or 0.5 mg through Dec. 31, 2026, then generally $349 for standard pen doses. Eligibility and dosage restrictions apply. Official source
- Zepbound (tirzepatide): LillyDirect self-pay: 2.5 mg starts at $299/28 days, 5 mg at $399, and 7.5 mg and above at $449 only with qualifying 45-day refill timing. Higher-dose prices can be higher when those conditions are not met. Supplies may cost extra. Official source
- Clinical program fees: Ivím lists a $74.99/month membership with medication billed separately. Sesame lists care from $59/month on a 12-month commitment; month-to-month costs more, and medication is separate. These are care fees, not all-inclusive drug prices. Official source
- Sesame annual-commitment terms: Official source.
These are manufacturer self-pay or listed care-fee examples, not one all-inclusive price or guaranteed prescription. Insurers, clinical visits, pharmacy choice, dosage, supplies, refill conditions and geography can change the amount due. Compounded GLP-1 products are not FDA-approved. Their availability, lawful compounding circumstances and product claims require separate verification. FDA policy.
If compounding ends, manufacturer savings programs become your primary path to affordable brand-name GLP-1s. Here's how NovoCare and LillyDirect actually compare.
Why These Programs Matter Now
Brand-name GLP-1 list prices remain steep — approximately $1,349/month for Wegovy and $1,080/month for Zepbound at lower doses. Without savings programs, the transition from $200–350/month compounded medication to brand-name would be unaffordable for most cash-pay patients.
Both Novo Nordisk (NovoCare) and Eli Lilly (LillyDirect) have created savings programs that significantly reduce out-of-pocket costs. The programs work differently, target different patient populations, and offer different levels of savings.
NovoCare (Wegovy/Ozempic)
NovoCare is Novo Nordisk's patient assistance platform. It offers savings cards for commercially insured patients (reducing copays to as low as $0–25/month for eligible patients), a Patient Assistance Program (PAP) for uninsured or underinsured patients with household income below certain thresholds, and the oral Wegovy launch pricing of $149/month for the starting dose through participating pharmacies and telehealth providers.
The oral Wegovy pathway is particularly significant post-compounding-ban. At $149/month for the starting dose, it's priced within the range of many compounded options. The daily pill format (taken on an empty stomach, 30-minute wait before eating) is a trade-off versus weekly injections, but eliminates injection anxiety entirely.
LillyDirect (Zepbound/Mounjaro)
LillyDirect is Eli Lilly's direct-to-patient channel. It offers Zepbound to cash-pay patients at reduced pricing starting from approximately $399/month for lower doses, with pricing increasing at higher dose tiers. The platform connects patients with prescribers and ships directly, bypassing traditional pharmacy intermediaries.
For patients who prefer tirzepatide over semaglutide — either because of better weight loss results (SURMOUNT data showed higher average weight loss than STEP trials) or better side effect tolerance — LillyDirect is the primary brand-name access pathway.
Head-to-Head Comparison
| Feature | NovoCare (Wegovy) | LillyDirect (Zepbound) |
|---|---|---|
| Medication | Semaglutide | Tirzepatide |
| Formats | Injectable + Oral pill | Injectable only |
| Cash-pay pricing | $149/mo (oral starter); varies (injectable) | From $399/mo |
| Insurance savings | Copay cards: $0–25/mo | Copay savings available |
| Patient assistance | Income-based PAP | Eligibility-based |
| CV risk reduction | Yes (SELECT trial) | Under study |
Our Recommendation
For cost-conscious cash-pay patients, start with oral Wegovy through NovoCare at $149/month. It's the most affordable brand-name entry point and eliminates injection concerns. For patients who want maximum weight loss potential, LillyDirect's Zepbound offers tirzepatide (which has shown higher average weight loss in clinical trials) starting at $399/month. For insured patients, check both programs' copay card eligibility — whichever medication your plan covers with the best copay is the right choice.
Compare Brand-Name Access
Find providers that can connect you with NovoCare or LillyDirect savings.
View Provider Comparison →